SCHEMBL3669079

SCHEMBL3669079

CCOC(COC(C)O[C]=O)OC

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3670956 0.90 LMNA (0.39) LMNA
SCHEMBL2652 0.80
SCHEMBL8919696 0.76
SCHEMBL3367366 0.73 ALDH1A1 (0.33)
SCHEMBL30973710 0.73 LMNA (0.39) LMNA
SCHEMBL9299455 0.73
SCHEMBL4396257 0.70 LMNA (0.48) LMNA
SCHEMBL1174723 0.69
SCHEMBL5694826 0.68
SCHEMBL1246847 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487494-B2 Cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA A/S (DK) 2016-11-08 US claimed
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-12-16 US claimed
EP-2234961-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-10-06 EP claimed
WO-2009065406-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2009-05-28 WO claimed
US-20240182631-A1 RANDOM COPOLYMER AND METHOD OF PRODUCING SAME ZEON CORPORATION (JP) 2024-06-06 US disclosed
EP-4317241-A1 RANDOM COPOLYMER AND METHOD FOR MANUFACTURING SAME Zeon Corporation (JP) 2024-02-07 EP disclosed
CN-116964124-A Random copolymer and method for producing same 日本瑞翁株式会社 2023-10-27 CN disclosed
WO-2022210407-A1 RANDOM COPOLYMER AND METHOD FOR MANUFACTURING SAME 日本ゼオン株式会社 2022-10-06 WO disclosed
EP-0702266-B1 Dry type image formation process FUJI PHOTO FILM CO LTD (JP) 2002-03-20 EP disclosed
US-5670292-A IMAGEWISE EXPOSING HEAT DEVELOPABLE PHOTOSENSITIVE MATERIAL TO LIGHT; RUPTURING MICROCAPSULES CONTAINING SILVER HALIDE FIXING AGENT FUJI PHOTO FILM CO., LTD. (JP) 1997-09-23 US disclosed
EP-0431568-B1 Method for processing a silver halide photographic material FUJI PHOTO FILM CO LTD (JP) 1996-10-16 EP disclosed
EP-0702266-A1 Dry type image formation process FUJI PHOTO FILM CO., LTD. (JP) 1996-03-20 EP disclosed
US-5415983-A Method for processing a silver halide photographic material FUJI PHOTO FILM CO., LTD. (JP) 1995-05-16 US disclosed
US-5401621-A Improved desilvering, nonstainig, stability FUJI PHOTO FILM CO., LTD. (JP) 1995-03-28 US disclosed
US-5192647-A Forming latent images FUJI PHOTO FILM CO., LTD. (JP) 1993-03-09 US disclosed
EP-0283041-B1 DIRECT POSITIVE SILVER HALIDE PHOTOSENSITIVE MATERIAL AND METHOD FOR FORMING DIRECT POSITIVE IMAGE FUJI PHOTO FILM CO., LTD. (JP) 1992-10-07 EP disclosed
EP-0496887-A1 PROCESS FOR TREATING SILVER HALIDE PHOTOGRAPHIC METERIAL AND COMPOSITION THEREFOR FUJI PHOTO FILM CO., LTD. (JP) 1992-08-05 EP disclosed
EP-0431568-A1 Method for processing a silver halide photographic material FUJI PHOTO FILM CO., LTD. (JP) 1991-06-12 EP disclosed
US-4952483-A NOVEL HYDRAZINE NUCLEATING AGENTS AND ACCELERATORS FUJI PHOTO FILM CO., LTD. (JP) 1990-08-28 US disclosed
US-4871653-A DEVELOPING IN PRESENCE OF MERCAPTO POLYAZAINDENE PROMOTERS AND NUCLEATING QUATERNARY OR HYDRAZIDE-TYPE COMPOUNDS FUJI PHOTO FILM CO., LTD. (JP) 1989-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES ARNT, AHR, CYP27A1 LMNA 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.